Tissue-Specific CRISPR Delivery System TissueGuide Gets FDA Fast Track: Gene Editing Achieves Precision Organ Targeting for the First Time

Intellia Therapeutics announced on November 4 that its TissueGuide tissue-specific CRISPR delivery system has received FDA Fast Track designation. This marks the first time CRISPR gene editing technology has achieved precise organ-targeted delivery.

Previous CRISPR therapies relied primarily on intravenous lipid nanoparticle injection, with drugs distributing systemically and limited amounts reaching target tissues. TissueGuide modifies the surface of lipid nanoparticles with tissue-specific ligand proteins, causing drugs to be preferentially internalized by cells in the target organ.

Intellia CEO John Leonard stated that TissueGuide currently supports three tissue targeting modes: liver targeting for hereditary transthyretin amyloidosis and other liver metabolic diseases, lung targeting for cystic fibrosis, and bone marrow targeting for sickle cell disease and beta-thalassemia.

In a Phase I/II clinical trial for hereditary transthyretin amyloidosis, a single TissueGuide injection reduced serum levels of the pathogenic protein by 93%, with the effect sustained beyond 12 months without decline. Off-target editing events were undetectable on whole-genome sequencing.

TissueGuide has received FDA Rare Pediatric Disease and Breakthrough Therapy designations. Intellia plans to submit a Biologics License Application in Q1 2029, with approval expected in the second half of the same year.

Gene editing therapy safety remains a regulatory priority. FDA Center for Biologics Evaluation and Research director Peter Marks stated that TissueGuides tissue-targeting design significantly reduces systemic off-target risk, though long-term safety data will require follow-up of five years or more.